120589-86-8

Basic information

• Product Name: 2(1H)-Quinoxalinone,4-acetyl-3,4-dihydro-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,4-acetyl-3,4-dihydro-(9CI);4-Acetyl-3,4-dihydro-1H-quinoxalin-2-one
• CAS NO: 120589-86-8
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.201
• Product Categories: PIPERIDINE
• Mol File: 120589-86-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly, Sonicated), DMSO (Slightly, Sonicated), Methanol (Slightly
• CAS DataBase Reference: 2(1H)-Quinoxalinone,4-acetyl-3,4-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,4-acetyl-3,4-dihydro-(9CI)(120589-86-8)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,4-acetyl-3,4-dihydro-(9CI)(120589-86-8)

Safety Data

• Hazardous Substances Data: 120589-86-8(Hazardous Substances Data)

Usage

General Description

2(1H)-Quinoxalinone,4-acetyl-3,4-dihydro-(9CI) is a chemical compound that belongs to the quinoxalinone family. It is a heterocyclic aromatic organic compound, with a molecular formula C11H10N2O2. 2(1H)-Quinoxalinone,4-acetyl-3,4-dihydro-(9CI) is typically found in the form of a white solid and is used in various research and industrial applications. It has been studied for its potential pharmacological properties, including as an inhibitor of certain enzymes and as an anti-cancer agent. Its structure and properties make it a versatile compound with potential uses in pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 5427-99-6 2-((2-nitrophenyl)amino)acetic acid 
• 1493-27-2 ortho-nitrofluorobenzene 
• 5428-05-7 n-(2-nitrophenyl)glycine ethyl ester 
• 674-82-8 4-methyleneoxetan-2-one 
• 59564-59-9 1,2,3,4-tetrahydroquinoxalin-2-one 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Relevant articles and documents

Quinoxalin-2(1H)-one derived AMPA-receptor antagonists: Design, synthesis, molecular docking and anticonvulsant activity

A new series of 4-acetyl-1-substituted-3,4-dihydroquinoxalin-2(1H)-ones (3–14) were designed and synthesized in order to evaluate their α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonism as a proposed mode of their anticonvulsant activity. The structure of the synthesized compounds was confirmed by elemental analysis and spectral data (infrared, 1H nuclear magnetic resonance (NMR), 13CNMR, and mass). The molecular design was performed for all synthesized compounds to predict their binding affinity towards AMPA-receptor in order to rationalize their anticonvulsant activity in a qualitative way and explain the possible interactions that might take place between the tested derivatives and AMPA receptor in comparing to compounds III and YM872 in order to obtain the anticonvulsant effect. The data obtained from the molecular modeling was strongly correlated with that obtained from the biological screening which revealed that; compounds 14b, 14a, and 13b showed the highest binding affinities toward AMPA-receptor and also showed the highest anticonvulsant activities against pentylenetetrazole-induced seizures in experimental mice. The relative potencies of these compounds were 1.89, 1.83, and 1.51 respectively, in comparing to diazepam.

Design, molecular docking and synthesis of some novel 4-acetyl-1-substituted-3,4-dihydroquinoxalin-2(1H)-one derivatives for anticonvulsant evaluation as AMPA-receptor antagonists

A new series of 4-acetyl-1-substituted-3,4-dihydroquinoxalin-2(1H)-ones (2–13) were designed and synthesized in order to evaluate their AMPA-receptor antagonism as a potential mode of anticonvulsant activity. The structure of the synthesized compounds was

Imidazo[1,5-A]quinoxalines

An invention relating to Imidazo[1,5-a]quinoxalines (I) STR1 which do not contain an endocyclic carbonyl group and which are useful as anxiolytic and sedative/hypnotic agents.